Ultragenyx Pharmaceutical

YTD

ALL

Trade Ultragenyx Pharmaceutical 24 hours a day, five days a week on Robinhood.

Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.

About RARE

Ultragenyx Pharmaceutical, Inc. is a biopharmaceutical company, which engages in the identification, acquisition, development, and commercialization of novel products for the treatment of genetic diseases. Its products include Crysvita, Mepsevii, Dojolvi, and Evkeeza.

CEO

Emil D. Kakkis

CEOEmil D. Kakkis

Employees

1,371

Employees1,371

Headquarters

Novato, California

HeadquartersNovato, California

Founded

2010

Founded2010

Employees

1,371

Employees1,371

RARE Key Statistics

Market cap

2.26B

Market cap2.26B

Price-Earnings ratio

-4.01

Price-Earnings ratio-4.01

Dividend yield

—

Dividend yield—

Average volume

2.45M

Average volume2.45M

High today

$23.46

High today$23.46

Low today

$22.50

Low today$22.50

Open price

$22.95

Open price$22.95

Volume

1.28M

Volume1.28M

52 Week high

$43.22

52 Week high$43.22

52 Week low

$18.41

52 Week low$18.41

Stock Snapshot

Ultragenyx Pharmaceutical(RARE) stock is priced at $23.39, giving the company a market capitalization of 2.26B. It carries a P/E multiple of -4.01.

During the trading session on 2026-03-01, Ultragenyx Pharmaceutical(RARE) shares reached a daily high of $23.46 and a low of $22.50. At a current price of $23.39, the stock is +4.0% higher than the low and still -0.3% under the high.

Trading activity shows a volume of 1.28M, compared to an average daily volume of 2.45M.

The stock's 52-week range extends from a low of $18.41 to a high of $43.22.

RARE News

Simply Wall St 4d

Ultragenyx Pharmaceutical Is Up 12.7% After FDA Grants Priority Review To DTX401 Gene Therapy - Has The Bull Case Changed?

Ultragenyx Pharmaceutical recently announced that the FDA accepted for review, with Priority Review, its Biologics License Application for DTX401 gene therapy t...

Simply Wall St 5d

A Look At Ultragenyx Pharmaceutical Valuation After FDA Priority Review For DTX401

Ultragenyx Pharmaceutical (RARE) is back in focus after the U.S. FDA accepted its Biologics License Application for DTX401, a gene therapy candidate for Glycoge...

TipRanks 6d

Ultragenyx Gains FDA Priority Review for DTX401 Therapy

The latest announcement is out from Ultragenyx Pharmaceutical ( (RARE) ). On February 23, 2026, Ultragenyx Pharmaceutical announced that the U.S. Food and Drug...

Analyst ratings

95%

of 22 ratings

Buy

95.5%

Hold

4.5%

Sell

People also own

Based on the portfolios of people who own RARE. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.